Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of Cabozantinib in Combination With Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Gastroesophageal Cancer and Other Gastrointestinal (GI) Malignancies (CAMILLA)

NCT03539822 is registered in ClinicalTrials.gov with Anwaar Saeed as lead sponsor.

NCT NCT03539822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03539822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of Cabozantinib in Combination With Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Gastroesophageal Cancer and Other Gastrointestinal (GI) Malignancies (CAMILLA)
Lead sponsor
Anwaar Saeed
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 22, 2018
Completion date
June 30, 2029
Enrollment
117 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, esophageal adenocarcinoma, gastric cancer, hepatocellular carcinoma